NAD+ Therapy: The Anti-Aging Breakthrough Now Available in New Jersey
Published by New Jersey Trim Clinic · Updated 2025-11-06
What Is NAD+ and Why Does It Matter?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell of your body. It is essential for converting food into energy, repairing damaged DNA, and regulating the genes that control aging.
Here is the catch: your NAD+ levels drop dramatically as you age. By age 50, most adults have less than half the NAD+ they had in their 20s. That decline is linked to fatigue, slower metabolism, brain fog, weakened immunity, and the visible signs of aging.
👉 Get the Promotional pricing: $189 New Jersey NAD+ Special — Call (239) 422-6350
Why NAD+ Therapy Is Surging in New Jersey
Restoring NAD+ has become one of the most-discussed anti-aging interventions in medicine. Patients across New Jersey are turning to physician-supervised NAD+ therapy because the benefits cover a broad range of what people are actually trying to fix:
- More steady energy without the caffeine crash cycle
- Sharper mental clarity and better focus
- Faster cellular repair at the DNA level
- Improved metabolism and fat-burning support
- Better sleep quality and recovery
- Stronger immune response
This is not a stimulant. It is not a vitamin. NAD+ therapy actually restores a foundational coenzyme your body uses every second of every day.
How NAD+ Works
When NAD+ is replenished, your mitochondria — the energy factories inside every cell — start producing ATP more efficiently. That alone explains the energy bump most patients describe within the first week or two.
NAD+ also activates a class of proteins called sirtuins, which are heavily involved in cellular repair, inflammation control, and longevity pathways. Studies on NAD+ continue to expand because the science keeps showing that restoring it has effects far beyond energy.
👉 Email info@newjerseytrimclinic.com or Call (239) 422-6350
Pairing NAD+ With GLP-1 Therapy
For New Jersey patients already on GLP-1 weight loss therapy (semaglutide or tirzepatide), NAD+ is a natural complement. GLP-1 medications support fat loss and appetite control. NAD+ supports the energy, recovery, and cellular health that make weight loss feel sustainable instead of exhausting.
Many of our NJ patients combine the two for a full metabolic and anti-aging protocol — and the results speak for themselves.
The Promotional pricing: $189 New Jersey NAD+ Special
We are running a New Jersey resident special on NAD+ therapy: Promotional pricing: $189 NAD+ — call for full details. This is a physician-supervised program, sourced through FDA-registered American compounding pharmacies, and coordinated entirely through telehealth.
Promotional pricing is limited and details vary based on your evaluation. Call or email to confirm what is included.
Is NAD+ Right for You?
NAD+ therapy is not for everyone — and that is exactly why we evaluate every patient first. A board-certified physician reviews your medical history, current health, and goals before prescribing.
If you are in your 30s or beyond, dealing with low energy, brain fog, slow recovery, or stalled weight loss, NAD+ may be the missing piece.
MEDICAL SOURCES & FURTHER READING
Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.
- NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity
Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.
- Mayo Clinic — Prescription weight-loss drugs
Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.
- Cleveland Clinic — GLP-1 Agonists
Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.
Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Supports: Semaglutide 2.4 mg plus lifestyle intervention produced weight loss in the STEP 1 randomized trial; gastrointestinal adverse events were reported.
Evidence limits: The main trial reported mean weight change of −14.9% at 68 weeks. This is not a predicted clinic outcome or proof that every semaglutide formulation has the same results.
- FDA — Wegovy (semaglutide) prescribing information
Supports: The approved product's label describes contraindications including personal or family history of medullary thyroid carcinoma and MEN 2, dose escalation, pregnancy considerations, gastrointestinal reactions, and warnings including pancreatitis, gallbladder disease and kidney injury due to volume depletion.
Evidence limits: This label is for Wegovy, not approval of New Jersey Trim Clinic or a compounded formulation. Individual prescribing decisions require a licensed provider.
- Tirzepatide Once Weekly for the Treatment of Obesity
Supports: The SURMOUNT-1 trial studied tirzepatide at different doses in adults with obesity or overweight without diabetes and reported weight reduction and gastrointestinal adverse events.
Evidence limits: SURMOUNT-1 was placebo-controlled, not a head-to-head comparison with semaglutide. Results do not establish guaranteed outcomes or equivalence of compounded medicines.
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Supports: A randomized study reported reduced hunger, food cravings and energy intake, and improved control of eating with semaglutide.
Evidence limits: This study does not establish a diagnosis of 'food noise', prove that all intrusive food thoughts have one cause, or show that every patient will experience relief. It found no evidence of delayed gastric emptying at week 20 using its indirect test.
- NIH/NIDDK — Factors Affecting Weight & Health
Supports: Weight is influenced by lifestyle, sleep, medicines, health conditions, family history and other factors; insufficient sleep can affect hunger.
Evidence limits: This general guidance does not establish the cause of an individual patient's cravings, emotional eating, insulin resistance or weight changes.
- FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.
Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.
- A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD
Supports: This exploratory pilot measured NAD+ and related metabolites during and after an intravenous infusion.
Evidence limits: It did not establish anti-aging, longevity, improved energy, cognition or clinical benefit, and did not study the clinic's injection regimen. A biological role for NAD+ does not prove a treatment benefit.
RESEARCH & REFERENCES
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. New England Journal of Medicine. 2021.
Research published in the New England Journal of Medicine reported greater weight reduction with semaglutide 2.4 mg plus lifestyle intervention than placebo in the studied adults without diabetes.
- Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. New England Journal of Medicine. 2022.
Research published in the New England Journal of Medicine reported dose-dependent weight reduction with tirzepatide versus placebo over 72 weeks in the studied population.
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. Diabetes, Obesity and Metabolism. 2021.
Research published in Diabetes, Obesity and Metabolism reported improvements in appetite and control of eating in a 20-week trial of semaglutide in adults with obesity.
- A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD
Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J. Frontiers in Aging Neuroscience. 2019.
Research published in Frontiers in Aging Neuroscience reported changes in plasma and urinary metabolites during an NAD+ infusion pilot, not evidence of improved longevity or anti-aging outcomes.
General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.
Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.